Results 1 to 10 of about 27,150 (219)

IL-1 Receptor Antagonist Anakinra Inhibits the Effect of IL-1β- Mediated Osteoclast Formation by Periodontal Ligament Fibroblasts [PDF]

Biology
Rheumatoid arthritis and periodontitis are comorbidities that share mutual pathways. IL-1β is a pro-inflammatory cytokine that plays a crucial role in both diseases.
Elizabeth Steemers, Wael M. I. Talbi, Jolanda M. A. Hogervorst, Ton Schoenmaker, Teun J. de Vries   +4 more
doaj   +2 more sources

Efficacy and Safety of Anakinra in Colchicine-Resistant or -Intolerant Familial Mediterranean Fever: A Single-Center Real-Life Experience [PDF]

Medicina
Familial Mediterranean Fever (FMF) is characterized by recurrent febrile attacks and serositis. While colchicine is the primary treatment for FMF, some patients present resistance or intolerance with respect to this drug.
Tuğba Ocak, Havva Nur Köse, Burcu Yağız, Belkıs Nihan Coşkun, Ediz Dalkılıç, Yavuz Pehlivan   +5 more
doaj   +2 more sources

Efficacy of Anakinra for Various Types of Crystal-Induced Arthritis in Complex Hospitalized Patients: A Case Series and Review of the Literature [PDF]

Mediators of Inflammation, 2015
Background. There are few data on anakinra use after failure of conventional medications for crystal-induced peripheral arthritis and/or crowned dens syndrome among complex hospitalized patients. Methods.
A. Aouba, S. Deshayes, L. Frenzel, A. Decottignies, C. Pressiat, B. Bienvenu, F. Boue, G. Damaj, O. Hermine, S. Georgin-Lavialle   +9 more
doaj   +7 more sources

Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trial.

PLoS ONE, 2022
ObjectiveWe aimed to investigate whether anakinra, an interleukin-1receptor inhibitor, could improve outcome in moderate COVID-19 patients.MethodsIn this controlled, open-label trial, we enrolled adults with COVID-19 requiring oxygen.
Alexandra Audemard-Verger, Amélie Le Gouge, Vincent Pestre, Johan Courjon, Vincent Langlois, Marc-Olivier Vareil, Mathilde Devaux, Boris Bienvenu, Vincent Leroy, Radjiv Goulabchand, Léa Colombain, Adrien Bigot, Thomas Guimard, Youcef Douadi, Geoffrey Urbanski, Jean François Faucher, Laurence Maulin, Bertrand Lioger, Jean-Philippe Talarmin, Matthieu Groh, Joseph Emmerich, Sophie Deriaz, Nicole Ferreira-Maldent, Ann-Rose Cook, Céline Lengellé, Hélène Bourgoin, Arsène Mekinian, Achille Aouba, François Maillot, Agnès Caille   +29 more
doaj   +2 more sources

The Endogenous Th17 Response in NO2-Promoted Allergic Airway Disease Is Dispensable for Airway Hyperresponsiveness and Distinct from Th17 Adoptive Transfer [PDF]

, 2013
Severe, glucocorticoid-resistant asthma comprises 5-7% of patients with asthma. IL-17 is a biomarker of severe asthma, and the adoptive transfer of Th17 cells in mice is sufficient to induce glucocorticoid-resistant allergic airway disease.
A Abe, A Duguet, A Hoshino, A Vazquez-Tello, A Vazquez-Tello, AG Besnard, AG Besnard, AI Caceres, AJ Coyle, AR Brasier, AR Sousa, AS Saffar, AT Hastie, B Korkmaz, Benjamin T. Suratt, BJ Canning, C Sutton, C Taube, D Stejskal, Daniel J. Weiss, DB Corry, DC Newcomb, DC Newcomb, DC Newcomb, DH Broide, E Goleva, F Kirstein, GJ Zijlstra, H Fujie, H Koga, H Wakashin, Hong Wei Chu, I Tillie-Leblond, J Agbetile, J Chang, J Seok, J Sunyer, J Zhao, JB Cowland, Jennifer L. Ather, JH Bates, JH Lee, JL Ather, JL Ather, John F. Alcorn, JR Karlsen, JV Fahy, K Raemdonck, K Yang, L McKinley, LA Cooney, Laura Hoyt, Lennart K. A. Lundblad, LJ Akinbami, LK Lundblad, LK Lundblad, LK Lundblad, LL Reber, M Bevelander, M Kawaguchi, M Kudo, M Leppkes, M Suzukawa, MA Willart, Matthew E. Poynter, ME Poynter, ME Poynter, ME Poynter, MH Brutsche, MH Shaw, MW Kinyanjui, N Schmitz, PA Wark, PL Delamater, PS Foster, PW Hellings, Q Wang, R He, RA Martin, Rebecca A. Martin, Rebecca Daggett, RH Wilson, S Ano, S Dragon, S Ferretti, S Haak, S Lajoie, S Molet, S Schnyder-Candrian, S Suzuki, S Wenzel, SJ Ballantyne, SM Hu, SP Chapoval, SR Hodgkins, T Li, VJ Johnson, W Al-Ramli, WP Arend, WW Lee, X Yao, XY Chi, Y Chung, Y Liu, Y Takenoue, Y Zhao, YH Wang   +106 more
core   +17 more sources

Anakinra for severe forms of COVID-19 [PDF]

The Lancet Rheumatology, 2020
International ...
Laine, Marc, Bonello, Laurent
  +13 more sources

Anakinra for recalcitrant pyoderma gangrenosum [PDF]

Clinical and Experimental Dermatology, 2021
Pyoderma gangrenosum (PG) is an autoinflammatory neutrophilic dermatosis characterized by rapidly enlarging, painful ulcers. Anakinra is a recombinant interleukin (IL)-1 receptor antagonist that blocks the activity of IL-1α and IL-1β by competitively inhibiting IL-1 binding to the IL-1 type 1 receptor.
Cathal O'Connor, Cathal O'Connor, Michael O'Connell, Catriona Gallagher, Lindsay Paul, Aoife Hollywood   +5 more
openaire   +4 more sources

Clinical outcomes and safety of anakinra in the treatment of multisystem inflammatory syndrome in children: a single center observational study

Pediatric Rheumatology Online Journal, 2023
Background and objective Evidence for the treatment of multisystem inflammatory syndrome in children (MIS-C) is lacking. Anakinra, which targets IL-1-mediated inflammation, is reserved for refractory cases of MIS-C; however, its use in the treatment of ...
Brian L.P. Dizon, Christopher Redmond, Emily C. Gotschlich, Sangeeta Sule, Tova Ronis, Kathleen M. Vazzana, Matthew A. Sherman, Rachael Connor, Abigail Bosk, Niti Dham, Ashraf S. Harahsheh, Elizabeth Wells, Roberta DeBiasi, Hemalatha Srinivasalu   +13 more
doaj   +1 more source

Continuous IV infusion of anakinra

Frontiers in Pharmacology, 2023
Objective: A review of the use of continuous IV infusion of anakinra; a description of the protocol for continuous IV infusion of anakinra in the treatment of cytokine storm developed over the past 4 years at a tertiary level academic medical center in the United States.Methods: We reviewed published reports of continuous IV infusion of anakinra in ...
Saunders, Brittney N., Kuijpers, Marcela V., Sloan, Jason J., Gertner, Elie   +3 more
openaire   +3 more sources

Intravenous administration of anakinra in children with macrophage activation syndrome

Pediatric Rheumatology Online Journal, 2021
Background Subcutaneous anakinra is an interleukin-1 inhibitor used to treat juvenile idiopathic arthritis. Recent reports suggest anakinra can be a valuable addition to the treatment of COVID-19 associated cytokine storm syndrome and the related ...
Omkar Phadke, Kelly Rouster-Stevens, Helen Giannopoulos, Shanmuganathan Chandrakasan, Sampath Prahalad   +4 more
doaj   +1 more source